325 related articles for article (PubMed ID: 31755238)
1. SGLT2 inhibitors for primary prevention of cardiovascular events.
Raz I; Cernea S; Cahn A
J Diabetes; 2020 Jan; 12(1):5-7. PubMed ID: 31755238
[No Abstract] [Full Text] [Related]
2. Increased grip strength with sodium-glucose cotransporter 2.
Sano M; Meguro S; Kawai T; Suzuki Y
J Diabetes; 2016 Sep; 8(5):736-7. PubMed ID: 27038414
[No Abstract] [Full Text] [Related]
3. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.
Vettor R; Inzucchi SE; Fioretto P
Diabetologia; 2017 Mar; 60(3):395-398. PubMed ID: 28074254
[No Abstract] [Full Text] [Related]
4. SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection.
Bell RM; Yellon DM
Lancet Diabetes Endocrinol; 2018 Jun; 6(6):435-437. PubMed ID: 29030201
[No Abstract] [Full Text] [Related]
5. The EMPA-REG study: What has it told us? A diabetologist's perspective.
DeFronzo RA
J Diabetes Complications; 2016; 30(1):1-2. PubMed ID: 26541076
[No Abstract] [Full Text] [Related]
6. Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment.
Bloomgarden Z
J Diabetes; 2013 Sep; 5(3):225-7. PubMed ID: 23714218
[No Abstract] [Full Text] [Related]
7. SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases.
Wanner C; Marx N
Diabetologia; 2018 Oct; 61(10):2134-2139. PubMed ID: 30132035
[TBL] [Abstract][Full Text] [Related]
8. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
[TBL] [Abstract][Full Text] [Related]
9. Dapagliflozine (Farxiga) for type 2 diabetes.
Med Lett Drugs Ther; 2014 Feb; 56(1436):13-5. PubMed ID: 24663030
[No Abstract] [Full Text] [Related]
10. Dapagliflozin, an SGLT2 inhibitor, for diabetes.
Hanefeld M; Forst T
Lancet; 2010 Jun; 375(9733):2196-8. PubMed ID: 20609956
[No Abstract] [Full Text] [Related]
11. [Focus on empagliflozin : post hoc analyses of the cardiovascular outcome trial EMPA-REG OUTCOME].
Scheen AJ
Rev Med Liege; 2019 Apr; 74(4):185-191. PubMed ID: 30997967
[TBL] [Abstract][Full Text] [Related]
12. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.
Lupsa BC; Inzucchi SE
Diabetologia; 2018 Oct; 61(10):2118-2125. PubMed ID: 30132031
[TBL] [Abstract][Full Text] [Related]
13. Introduction.
Chilton R
Am J Med; 2017 Jun; 130(6S):S1-S3. PubMed ID: 28526180
[No Abstract] [Full Text] [Related]
14. SGLT2 inhibitors and renal function.
Med Lett Drugs Ther; 2016 Jul; 58(1499):91-2. PubMed ID: 27403782
[No Abstract] [Full Text] [Related]
15. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
[TBL] [Abstract][Full Text] [Related]
16. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.
Wittbrodt ET; Eudicone JM; Bell KF; Enhoffer DM; Latham K; Green JB
Am J Manag Care; 2018 Apr; 24(8 Suppl):S138-S145. PubMed ID: 29693360
[TBL] [Abstract][Full Text] [Related]
17. Considerations for SGLT2 inhibitor use in post-transplantation diabetes.
Hecking M; Jenssen T
Nat Rev Nephrol; 2019 Sep; 15(9):525-526. PubMed ID: 31235880
[No Abstract] [Full Text] [Related]
18. Human and mouse non-targeted metabolomics identify 1,5-anhydroglucitol as SGLT2-dependent glycemic marker.
Kappel BA; Moellmann J; Thiele K; Rau M; Artati A; Adamski J; Ghesquiere B; Schuett K; Romeo F; Stoehr R; Marx N; Federici M; Lehrke M
Clin Transl Med; 2021 Jun; 11(6):e470. PubMed ID: 34185398
[No Abstract] [Full Text] [Related]
19. [SGLT2 inhibition in type 2 diabetes. New study data for reducing cardiovascular risk].
MMW Fortschr Med; 2015 Oct; 157(18):86-7. PubMed ID: 26985517
[No Abstract] [Full Text] [Related]
20. [Positive experience with SGLT-2 inhibitor in general practice].
Fath R
MMW Fortschr Med; 2015 Jul; 157(13):83. PubMed ID: 26206058
[No Abstract] [Full Text] [Related]
[Next] [New Search]
